Protagonist Therapeutics, Inc. (PTGX) Q4 2016 Earnings Results

Protagonist Therapeutics Misses on EPS — Stock Down 1.46%

Protagonist Therapeutics reported a larger-than-expected loss per share, which contributed to a 1.46% decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's near-term prospects. The management's focus on research and development suggests they are prioritizing long-term growth despite current financial challenges.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.67	N/A	-36.73%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management acknowledged the challenges faced in the quarter. They highlighted their commitment to advancing their pipeline despite the lack of financial guidance.

Management did not provide specific guidance for future quarters.

The company emphasized ongoing research and development efforts.

Protagonist Therapeutics Misses on EPS — Stock Down 1.46%

Key numbers

Management commentary

Protagonist Therapeutics, Inc.

More earnings this week

Protagonist Therapeutics Misses on EPS — Stock Down 1.46%

Key numbers

Management commentary